Transgenic Chickens using Primordial Germ Cells

使用原始生殖细胞的转基因鸡

• 批准号: 7054360
• 负责人: MARIE-CECILE VAN DE LAVOIR
• 金额: $ 63.13万
• 依托单位: ORIGEN THERAPEUTICS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7054360
• 关键词: antibody; bioengineering /biomedical engineering; chickens; chimeric proteins; developmental genetics; genetically modified animals; immunoglobulins; immunologic substance development /preparation; immunotherapy; method development; monoclonal antibody; nonmammalian vertebrate embryology; pluripotent stem cells; site directed mutagenesis; transfection; transposon /insertion element

DESCRIPTION (provided by applicant): Origen Therapeutic's goal is to develop chickens that produce fully human monoclonal and polyclonal antibodies. To achieve this aim the chicken Origen needs the capability to insert and modify the chicken genome and to transmit these genomic modifications through the germline. Origen's platform centers around a cell based system that allows integration of large pieces of DNA and allows precise deletions in the genome. To this end Origen has identified a cell population that has the potential to enter the germline. This application focuses on transfecting this cell population with large (150 kb) constructs and to knock-out specific genes within the chicken genome. These transfected cell popupations will then be trafficked through the germline to obtain a flock of transgenic chickens.

描述（由申请人提供）：Origen Therapeutic的目标是开发能够产生完全人源单克隆抗体和多克隆抗体的鸡。为了实现这一目标，鸡Origen需要能够插入和修饰鸡基因组，并通过种系传递这些基因组修饰。Origen的平台围绕着一个基于细胞的系统，该系统允许整合大块DNA并允许基因组中的精确缺失。为此，Origen已经确定了一个有潜力进入生殖系的细胞群。本申请的重点是用大的（150 kb）构建体来克隆该细胞群体，并敲除鸡基因组中的特定基因。这些转染的细胞群然后将通过生殖系被运输以获得一群转基因鸡。